Clinical Trials Arena April 2, 2025
Patient engagement through advisory boards, surveys, and listening sessions can help address industry challenges such as trial delays.
As advocacy efforts bolster the need for patient-focused drug development, amidst regulatory encouragement, the value of listening to patients is being realised in a more actionable manner.
“You can paint a fuller picture by hearing directly from patients,” said Richie Kahn, co-founder and COO of Canary Advisors.
Kahn was speaking at the ongoing Outsourcing in Clinical Trials Southeast 2025 conference, being held 1–2 April in Cary, North Carolina. Kahn, who has participated in clinical trials, advocated for more people in the field to do the same to understand the patient perspective more accurately.
The sector’s reaction to patient-focused drug development (PFDD) has...
Today's Sponsors
Today's Sponsor